If you're using semaglutide or tirzepatide for weight management and you're also thinking about starting or growing your family, timing matters. GLP-1 medications work well for many people managing their weight, but pregnancy changes the calculus in a few specific, well-documented ways. This article walks through what FDA labeling says about GLP-1 medications and pregnancy, why clinicians generally recommend stopping before you try to conceive, how these medications can interact with hormonal birth control, and what's known about use while breastfeeding.
This is patient education, not medical advice. It is not a substitute for an individualized evaluation, and it does not create a doctor-patient relationship. Only an independent licensed clinician can advise you on the right timing for your specific situation, your medication, and your health history.
Why pregnancy planning matters if you're using a GLP-1 medication
Weight management medications are typically prescribed with the expectation of ongoing use, sometimes for months or years, which means the question of pregnancy planning eventually comes up for a meaningful share of the people using them. Whether you're actively trying to conceive, thinking about it in the next year, or simply want to understand the guidance before you need it, this is worth discussing with your clinician early rather than waiting until a pregnancy test is positive.
Part of the reason this needs planning, rather than a same-day decision, is how these medications are dosed. Semaglutide and tirzepatide are long-acting, once-weekly injections (or, for some compounded and oral forms, daily dosing), and they don't clear from the body quickly. That has direct implications for how far in advance a clinician will typically recommend stopping treatment before conception.
What FDA labeling says about GLP-1 medications and pregnancy
FDA-approved prescribing information for GLP-1 medications used in weight management, including Ozempic® and Wegovy® (semaglutide) and Mounjaro® and Zepbound™ (tirzepatide), recommends discontinuing the medication at least 2 months before a planned pregnancy. That window reflects the time needed for the medication to clear the body, given its long-acting, once-weekly design.
The key point
FDA labeling for GLP-1 medications used in weight management recommends stopping at least 2 months before a planned pregnancy. This isn't a suggestion to wait until you notice a missed period; it's meant to be planned in advance.
The underlying reason for this guidance is straightforward: animal reproduction studies have shown risks to a developing fetus at exposures relevant to human use, and there is limited data on how these medications affect pregnancy in humans, since pregnant people are not included in the clinical trials that support FDA approval. Limited data does not mean a medication is known to be harmful; it means there isn't enough evidence yet to say how it behaves during pregnancy, and clinicians err toward caution as a result.
| Situation | General guidance |
|---|---|
| Planning a pregnancy | FDA labeling recommends stopping semaglutide or tirzepatide at least 2 months before trying to conceive |
| Already pregnant | Contact your clinician promptly to discuss discontinuing treatment and transitioning to prenatal care |
| Using oral hormonal birth control | Delayed gastric emptying may reduce absorption; a non-oral method or added barrier method is often recommended |
| Breastfeeding | Data are limited; a clinician weighs the known benefits of breastfeeding against any unknown effects |
| Compounded vs FDA-approved | The same pregnancy-planning guidance applies, since the active molecule works the same way either way |
Why clinicians recommend stopping before a planned pregnancy
The 2-month window isn't an arbitrary rule; it reflects how these medications are cleared from the body. Semaglutide and tirzepatide are designed for once-weekly dosing precisely because they stay active in the body for an extended period. That same property, which is useful for steady, once-a-week treatment, is also why it takes time for the medication to clear once you stop.
Stopping early enough means that by the time conception occurs, the medication is largely out of your system rather than still active during the earliest, most sensitive weeks of fetal development. This is a common approach with many medications that lack robust pregnancy safety data, not something unique to GLP-1 treatment: when a medication hasn't been well studied in pregnancy, the more conservative and generally recommended path is to clear it from the body well before conception rather than to continue it and hope for the best.
If a pregnancy happens sooner than planned, or before you've had a chance to stop treatment, that's a reason to contact your clinician promptly, not a reason to panic. Your clinician can talk through next steps, including discontinuing the medication and coordinating with an OB-GYN or midwife for prenatal care.
Weight loss and pregnancy: why they don't mix
Beyond the medication itself, there's a separate reason GLP-1 treatment and pregnancy don't overlap well: weight loss is generally not recommended during pregnancy. Pregnancy typically requires weight gain to support fetal growth and development, and the amount of recommended gain varies by a person's starting weight and is something an OB-GYN determines individually. Actively trying to lose weight while pregnant runs counter to that goal.
This is worth keeping in mind even beyond the medication timing question. If your plans shift and pregnancy becomes a nearer-term goal than expected, that's a good moment to revisit your treatment plan with your clinician rather than continuing on the same trajectory. Weight management and pregnancy preparation are both legitimate goals, but they're sequential rather than simultaneous ones.
GLP-1 medications and hormonal birth control
If you're using a GLP-1 medication and want to avoid pregnancy rather than plan one, it's worth understanding how these medications can interact with hormonal contraception. Because GLP-1 medications delay gastric emptying, they may reduce how well oral hormonal contraceptives are absorbed, particularly around the time you start treatment or after a dose increase, when the digestive effects tend to be most pronounced.
For this reason, a non-oral contraceptive method, such as an intrauterine device, implant, patch, or injection, is often recommended for people on GLP-1 treatment who want reliable contraception, or an added barrier method (like condoms) for a period of time after starting or increasing the dose. This is a conversation worth having directly with your clinician or the prescriber managing your contraception, since the right approach depends on which GLP-1 medication and dose you're using and which contraceptive method you currently rely on.
The key point
GLP-1 medications are not a form of contraception, and they can reduce the reliability of oral birth control pills. If avoiding pregnancy is a priority, ask your clinician whether a non-oral method or an added barrier method makes sense for you.
Breastfeeding and postpartum considerations
If you've had a baby and are considering restarting GLP-1 treatment while breastfeeding, that's another situation where the evidence is still developing. Data on GLP-1 medication use during breastfeeding are limited, so a clinician has to weigh the known, well-established benefits of breastfeeding against any potential, still-unclear effects of the medication passing into breast milk.
This isn't a situation with a single right answer that applies to everyone. Some clinicians may recommend waiting until breastfeeding has ended before restarting treatment; others may take a different approach depending on your individual health picture. What matters most is having that conversation directly with your prescriber, and being upfront with your pediatrician and OB-GYN about any medications you're considering during this period.
You can find more on how GLP-1 treatment typically unfolds once it's underway in our guide to what to expect in your first month of GLP-1 treatment, and on the mechanism behind these medications in how compounded GLP-1s work.
Talking to your clinician about timing
Because pregnancy planning touches both medication timing and contraception, it's a topic worth raising proactively rather than waiting for your clinician to ask. A few specifics tend to make that conversation more productive:
- Your general timeline, even a rough one, whether you're actively trying, thinking about it in the coming months, or simply want the guidance on record for later.
- Your current contraceptive method, if avoiding pregnancy is still the goal, so your clinician can flag any interaction with your current GLP-1 dose.
- Whether you're using an FDA-approved brand, such as Ozempic® or Wegovy®, or a compounded formulation, since the same pregnancy-planning guidance applies either way but your clinician will want the specifics on record.
- Any other medications or supplements you're taking, since your OB-GYN or midwife will want a complete picture once you transition to prenatal care.
Your clinician can help you sequence things sensibly: continuing treatment while contraception is reliable, then building in the discontinuation window well ahead of when you plan to start trying, rather than making the decision under time pressure.
The bottom line
GLP-1 medications and pregnancy planning intersect in a few concrete ways. FDA labeling recommends discontinuing semaglutide or tirzepatide at least 2 months before a planned pregnancy, weight loss itself is not recommended during pregnancy, and these medications may reduce the reliability of oral hormonal birth control, which is worth addressing with a non-oral or added barrier method if avoiding pregnancy is your goal. Data on use during breastfeeding are still limited. None of this needs to be worked out alone. A licensed clinician can help you plan the timing around your specific goals and medication.
You can find more on related topics in our Weight Management section.
Important Safety Information
Indication. Semaglutide and tirzepatide are GLP-1 receptor agonist medications that a licensed physician may prescribe for chronic weight management when clinically appropriate, alongside a reduced-calorie diet and increased physical activity. FDA-approved brand products include Ozempic® and Wegovy® (semaglutide) and Mounjaro® and Zepbound™ (tirzepatide); compounded versions are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality, but may be prescribed by an independent licensed physician when clinically appropriate.
Common side effects. The most commonly reported side effects are gastrointestinal, including nausea, diarrhea, vomiting, constipation, and abdominal discomfort. These are often mild and tend to ease over time, particularly as the dose is increased gradually.
Warnings. These medications may cause serious side effects, including a boxed warning relating to thyroid C-cell tumors seen in rodent studies; they should not be used by people with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. Tell your provider about any history of pancreatitis, gallbladder disease, kidney problems, or if you are pregnant, planning to become pregnant, or breastfeeding, since FDA labeling recommends discontinuing treatment at least 2 months before a planned pregnancy.
Talk to your doctor. This information is educational and is not a substitute for medical advice. Only a licensed medical professional can determine whether a treatment is right for you. Talk to your doctor about the benefits and risks, and report any side effects.
Frequently asked questions
Can I take semaglutide or tirzepatide while trying to get pregnant?
Generally, no. FDA labeling for GLP-1 medications used in weight management recommends discontinuing the medication at least 2 months before a planned pregnancy, since these medications take time to clear the body and haven't been well studied in pregnant people.
Why does a GLP-1 medication need to be stopped 2 months before trying to conceive?
Semaglutide and tirzepatide are long-acting, once-weekly medications, so they don't clear the body quickly. The 2-month window is meant to ensure the medication is largely out of your system before conception, during the earliest and most sensitive weeks of fetal development.
Is it safe to try to lose weight while pregnant?
Weight loss is generally not recommended during pregnancy. Pregnancy typically requires weight gain to support fetal growth and development, and the appropriate amount is something an OB-GYN determines individually based on your starting weight and health history.
Does semaglutide or tirzepatide affect birth control pills?
It can. Because GLP-1 medications delay gastric emptying, they may reduce how well oral hormonal contraceptives are absorbed, especially around starting treatment or after a dose increase. A non-oral method or an added barrier method is often recommended if avoiding pregnancy is your goal.
What should I do if I find out I'm pregnant while taking a GLP-1 medication?
Contact your clinician promptly to discuss discontinuing the medication and coordinating prenatal care with an OB-GYN or midwife. This is a common situation to plan for, not a reason to panic, and your clinician can walk you through next steps.
Does this guidance apply to compounded semaglutide and tirzepatide too?
Yes. The same pregnancy-planning guidance applies whether you're using an FDA-approved brand or a compounded formulation, since the active molecule works the same way either way. Compounded medications are not FDA-approved and have not been reviewed by the FDA for safety, efficacy, or quality, but may be prescribed by an independent licensed physician when clinically appropriate.
